Our study revealed that GP39 is increased in patients after aneurysm stenting and that GP39 may be a useful biomarker for monitoring cerebrovascular disease and assessing the efficacy of endovascular treatments. This evidence concerns the gene CHI3L1 and cerebrovascular disorder.